J Am Coll Cardiol by Lloyd-Jones, Donald M. et al.
Estimating Longitudinal Risks and Benefits From Cardiovascular 
Preventive Therapies Among Medicare Patients: The Million 
Hearts Longitudinal ASCVD Risk Assessment Tool:
A Special Report From the American Heart Association and American College of 
Cardiology
Donald M. Lloyd-Jones, MD, ScM, FAHA, FACC,
Northwestern University Center for Medicare and Medicaid Innovation
Mark D. Huffman, MD, MPH, FAHA, FACC,
Northwestern University Preventive Medicine
Kunal N. Karmali, MD, MS, FACC,
Northwestern University Preventive Medicine
Darshak M. Sanghavi, MD,
Centers for Medicare and Medicaid Services
Janet S. Wright, MD, FACC,
CDC/CMMI Million Hearts CMS Innovations Center
Colleen Pelser, PhD,
The MITRE Corp
Martha Gulati, MD, MS, FAHA, FACC,
University of Arizona
Frederick A. Masoudi, MD, MSPH, FAHA, FACC, and
University of Colorado & Colorado Cardiovascular Outcomes Consortium
David C. Goff Jr., MD, PhD, FAHA
Colorado School of Public Health
Abstract
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the 
express permission of the American College of Cardiology Foundation. Requests may be completed online via the Elsevier site (http://
www.elsevier.com/about/policies/author-agreement/obtaining-permission).
Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org) and the 
American Heart Association (professional.heart.org). For copies of this document, please contact Elsevier Reprint Department, fax 
(212) 633-3820 or e-mail reprints@elsevier.com. 
The American Heart Association and the American College of Cardiology make every effort to avoid any actual or potential conflicts 
of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the 
writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing 
all such relationships that might be perceived as real or potential conflicts of interest.
This document was approved by the American Heart Association Science Advisory and Coordinating Committee on September 30, 
2016, and the American Heart Association Executive Committee on October 17, 2016, and by the American College of Cardiology 
Board of Trustees on October 7, 2016.
HHS Public Access
Author manuscript
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 28.
Published in final edited form as:













The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes—the 
leading causes of mortality—through several public health and healthcare strategies by 2017. The 
American Heart Association and American College of Cardiology support the program. The 
Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for 
Medicare & Medicaid Services as a strategy to asses a value-based payment approach toward 
reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by 
implementing cardiovascular preventive strategies to manage the “ABCS” (aspirin therapy in 
appropriate patients, blood pressure control, cholesterol management, and smoking cessation).
The purpose of this special report is to describe the development and intended use of the Million 
Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and 
builds on the “2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk” by allowing 
clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention 
patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides 
updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses 
of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-
reducing therapies in primary prevention may help target therapies to those in whom they will 
provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services 
program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.
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Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality and 
major morbidity in the United States, particularly among older Americans.1 The incidence 
of ASCVD events increases dramatically with each decade of life after 45 years of age in all 
sex and racial/ethnic groups. Most heart attacks and strokes occur in older adults as a result 
of cumulative exposure to preventable or modifiable causal risk factors that arise from 
adverse environmental conditions and behavioral/lifestyle patterns, including elevated blood 
pressure, adverse atherogenic blood lipid levels, diabetes mellitus, and tobacco use. 
Primordial prevention—preventing the development of these adverse risk factors in the first 
place— represents a promising and essential strategy for future control of ASCVD in the 
United States.2 However, a substantial amount of risk is already present among older 
Americans, who will require primary preventive interventions using evidence-based 
therapies to reduce their ASCVD risk.
THE MILLION HEARTS INITIATIVE: PREVENTING 1 MILLION HEART 
ATTACKS AND STROKES
In 2012, the US Department of Health and Human Services (HHS) initiated Million Hearts, 
a national public-private initiative with an ambitious goal of preventing 1 million heart 
attacks and strokes by 2017.3 The Centers for Disease Control and Prevention and the 
Centers for Medicare & Medicaid Services (CMS) co-lead the initiative on behalf of HHS. 
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The American Heart Association (AHA) and American College of Cardiology (ACC) have 
enthusiastically supported the program.
Million Hearts aims to prevent heart attacks and strokes by pursuing a number of public 
health and healthcare strategies, outlined in Table 1.4 Central to the implementation of these 
strategies is management of the “ABCS”—aspirin therapy in appropriate patients, blood 
pressure control, cholesterol management, and smoking cessation. Identification of 
individuals at high risk for ASCVD, in whom application of these evidence-based therapies 
would have the greatest benefit, and improving adherence to these therapies once prescribed 
are essential for achieving these goals.
In support of Million Hearts, the Center for Medicare & Medicaid Innovation (CMMI) of 
the CMS recently announced its plans to perform a large cluster randomized payment model 
test of value-based payment designed to determine whether financially rewarding reductions 
in 10-year predicted risk for ASCVD across a physician’s patient population is an effective 
model to reduce the burden of heart attack and stroke.5 This Cardiovascular Risk Reduction 
Model will represent the largest test of value-based prevention payment conducted by CMS. 
As described by Sanghavi and Conway:
Medicare beneficiaries will be encouraged to “know [their] numbers,” share 
decision making with their physicians, and choose from a menu of options (for 
example, controlling blood pressure…, taking daily aspirin, or eliminating tobacco 
use) tailored to the patient’s readiness. The model’s value-based payment design 
will reward not specific blood pressure values or cholesterol target numbers but 
rather reduction in predicted risk of myocardial infarction and stroke. On the 
payment side, clinicians will be rewarded on a sliding scale tiered by absolute risk 
reduction across their entire high-risk patient panel, which increases incentives for 
health management of entire cohorts of patients. An additional benefit is that 
overtreatment of individuals at low risk could be minimized because overtreatment 
is not rewarded significantly.5
To conduct the test of the Cardiovascular Risk Reduction Model, CMS solicited the creation 
of the Million Hearts Longitudinal ASCVD Risk Assessment Tool, an innovative tool that 
predicts baseline 10-year ASCVD risk, projects changes in ASCVD risk that would be 
expected with initiation of and adherence to evidence-based therapies, and incorporates 
individual patient responses to these therapies over time to allow for dynamic, longitudinal 
ASCVD risk prediction. The model was developed by CMMI in collaboration with a 
research and development team from the CMS Alliance to Modernize Healthcare (CAMH), 
a federally funded research and development center (FFRDC) operated by the The MITRE 
Corporation for HHS. In this special report, we describe the development of the 
Longitudinal ASCVD Risk Estimator that was designed to support the overarching Million 
Hearts Cardiovascular Risk Reduction Model to be tested, and its application in clinical 
practice.
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Primary Prevention of ASCVD
Effective strategies exist for the primary prevention of ASCVD,6 but they are currently 
underutilized or not applied to the appropriate spectrum of patients, with clear 
undertreatment of higher-risk patient groups for whom efficacy has been demonstrated.1,7,8 
Aspirin prevents ASCVD in certain groups, but its use must be weighed against the risk for 
major bleeding.9–11 Decades of research have demonstrated the benefits of blood pressure–
lowering medications among individuals with elevated blood pressure, including among 
those with modest elevations in blood pressure but elevated global ASCVD risk.12–16 
Likewise, in the past 20 years, statin medications have emerged as safe and highly effective 
medications for ASCVD primary prevention among essentially all groups at higher risk for 
ASCVD,17–20 with the exception of those on hemodialysis. Tobacco cessation substantially 
reduces ASCVD risk, and effective drugs and behavioral interventions can improve rates of 
smoking cessation.21
The “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce 
Atherosclerotic Cardiovascular Risk in Adults”22 identified 4 groups of patients for whom 
net clinical benefit of statin therapy has been demonstrated in randomized clinical trials: (1) 
patients with clinical ASCVD; (2) individuals with low-density lipoprotein (LDL)-
cholesterol ≥190 mg/dL not attributable to secondary causes; (3) patients aged 40 to 75 years 
with diabetes mellitus and LDL-cholesterol 70 to 189 mg/dL; and (4) patients aged 40 to 75 
years with estimated 10-year risk for ASCVD ≥7.5%. The last group represents those 
patients who need primary prevention of ASCVD as a result of elevated risk attributable to 
combinations of risk factors in the context of age, sex, and race/ethnicity. Despite the 
demonstrated benefits of pharmacological interventions (the ABCS), these therapies are 
often underutilized in populations with existing ASCVD23,24 as well as among higher-risk 
individuals eligible for primary prevention of ASCVD events.8
Current Paradigm for ASCVD Primary Prevention
The current paradigm for decision-making in the primary prevention of ASCVD is that the 
intensity of prevention efforts should be calibrated to the absolute ASCVD risk. This 
paradigm was promulgated in 1996,25 operationalized in the Third Adult Treatment Panel 
cholesterol guidelines (ATP III) in 200126 and 2004,27 and endorsed by the 2013 ACC/AHA 
guidelines on risk assessment28 and cholesterol management.22 Under this paradigm, 
individuals at low absolute predicted risk for ASCVD in the near term (<10 years) are 
recommended for all appropriate lifestyle modifications (eg, tobacco cessation, dietary and 
physical activity improvements), whereas those at higher predicted risk should receive 
lifestyle counseling as well as consideration for immediate drug therapy (eg, aspirin, blood 
pressure–lowering therapies, and statins) to reduce risk. Central to the approach to primary 
prevention in the 2013 ACC/AHA cholesterol guidelines is shared decision-making between 
the patient and clinician that begins with estimation of the patient’s absolute 10-year 
ASCVD risk, incorporates individual factors that may revise the risk estimate (up or down), 
considers the expected benefits and potential harms that would be expected from statin 
therapy, and includes patient preferences.22
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The approach to basing decision-making on absolute ASCVD risk has been adopted widely 
by US and international guidelines and professional societies and permits more efficient and 
appropriate selection of patients for pharmacological treatment compared with usual 
care.29–31 Use of the 2013 ACC/AHA risk-based approach would prevent more events and 
treat fewer patients than an approach based solely on inclusion/exclusion criteria from 
randomized clinical trials, or a hybrid approach based on risk and the trials’ inclusion/
exclusion criteria.32 A recent simulation suggested the use of individualized statin benefit 
estimation for younger, lower-risk individuals.33 Although current US hypertension 
guidelines recommend drug therapy solely based on blood pressure levels, studies also 
suggest that selecting patients by absolute predicted short-term ASCVD risk would be a 
more efficient means of determining benefit from antihypertensive therapy.29,31 Likewise, 
given the known risks for major bleeding associated with aspirin therapy, guidelines have 
adopted an approach that compares the expected benefit from aspirin in reducing heart 
attack and stroke balanced against the absolute risk for bleeding, to understand the net 
clinical benefit of aspirin.9,11
Estimating Baseline ASCVD Risk in Primary Prevention
A critical component of the approach to ASCVD risk reduction in the 2013 ACC/AHA22,28 
and other guidelines is the estimation of the 10-year risk for preventable ASCVD events 
(including coronary death, nonfatal myocardial infarction, and fatal or nonfatal stroke) for 
individual patients, followed by application of evidence-based thresholds to determine 
eligibility for drug therapy. The 2013 ACC/AHA risk assessment guidelines developed new 
multivariable equations (the “Pooled Cohort Equations”) to provide sex- and race-specific 
estimates of ASCVD risk for black and Non-Hispanic white American men and women 
based on age, total and high-density lipoprotein (HDL)-cholesterol levels, systolic blood 
pressure (SBP), antihypertensive treatment use, diabetes mellitus history, and current 
smoking status. These equations were developed specifically to provide sex- and race-
specific estimates for the first time, and to include strokes in addition to CHD in the 
outcome, which allows for better representation of preventable risk among women and 
blacks. Other outcomes, such as elective revascularization procedures, were not included 
because of their poor correlation with patient characteristics and extreme geographic 
variation in rates.28
The 2013 Pooled Cohort Equations for estimating ASCVD risk in the US population were 
derived from 5 community- and population-based studies, including the Framingham Heart 
Study, Framingham Offspring Study, ARIC (Atherosclerosis Risk in Communities) study, 
CHS (Cardiovascular Health Study), and CARDIA (Coronary Artery Risk Development in 
Young Adults) study. Data from ~25,000 individuals aged 40 to 79 years were available.28 
To date, these equations have been evaluated in the derivation cohorts and validated in 
several external cohorts. Some have noted a mismatch between predicted risk from the 
equations and observed risk during follow-up; overestimation of risk by the equations tends 
to be observed in selected healthy volunteer cohorts who tend to have higher socioeconomic 
status and/or who were intensively treated with preventive therapies after inception that 
would alter the natural history of ASCVD.34–36 Others have noted underestimation of risk 
by the Pooled Cohort Equations in patient groups with inflammatory conditions, such as 
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HIV.37 In contrast, the equations have demonstrated good discrimination and excellent 
calibration around decision thresholds in cohorts that are population-based and broadly 
representative of the United States, specifically including Medicare-eligible participants.38 
In the REGARDS cohort (REasons for Geographic And Racial Differences in Stroke), 
which includes community-dwelling individuals from all 48 contiguous Unites States and 
large numbers of black and white participants, the Pooled Cohort Equations were overall 
well-calibrated, including among Medicare participants. Among groups at the highest 
predicted risk levels, the Pooled Cohort Equations predicted somewhat higher ASCVD rates 
than were observed, likely attributable to use of preventive therapies during follow-up.38 
Clinicians therefore should be aware that the Pooled Cohort Equations, like all such risk 
assessment tools, estimate risk for patient groups and perform best in patient samples that 
resemble the derivation populations.
Similarly, the approach of the 2013 ACC/AHA cholesterol and risk assessment guidelines is 
substantially better than the older ATP III approach in sensitivity for detecting which 
patients will experience myocardial infarction39 and in identifying patients with a significant 
burden of coronary atherosclerosis.40–42 The current approach also has an acceptable 
number-needed-to-treat to prevent a ASCVD event43 and is cost-effective by current 
standards.44 It is estimated that the 2013 ACC/AHA guideline approach to cholesterol 
reduction could reduce the number of ASCVD events in the United States by 475,000 in the 
next decade, compared with the ATP III guideline approach, most of which would occur in 
older individuals who are at highest risk for ASCVD.45 Full implementation of the 2013 
ACC/AHA cholesterol guidelines approach in all untreated, statin eligible adults could 
achieve 78% of the Healthy People 2020 ASCVD prevention goal, with most of the benefits 
accruing to older, higher-risk individuals.46
Estimating Potential Benefits of ASCVD Risk-Reducing Therapies in Individual Patients
After estimating the baseline ASCVD risk, clinicians and patients currently have few tools 
to help them select and prioritize the most important or effective therapies to reduce ASCVD 
risk in the near term. As noted, the 2013 Pooled Cohort Equations predict the absolute 10-
year risk for an incident ASCVD event if an individual with that profile at baseline were not 
treated with additional preventive therapies (ie, their “natural history”). It may be tempting 
to use these equations also as a means of estimating the benefits of interventions, by 
updating risk factor levels in the same equations. For example, one could attempt to provide 
an updated 10-year ASCVD risk by incorporating data on a patient’s new (presumably 
lower) blood pressure level after initiating antihypertensive therapy.
However, estimating the effect of a given therapy on updated 10-year risk simply by 
changing a risk factor level or removing adverse risk factors in the Pooled Cohort Equations 
(or any other similar risk prediction equations) provides inaccurate results. For example, a 
70-year-old black man who does not have diabetes mellitus and is not a current smoker, with 
a total cholesterol of 200 mg/dL and HDL-cholesterol of 50 mg/dL and an untreated SBP of 
150 mm Hg, has a 10-year predicted ASCVD risk of 15.3%, per the Pooled Cohort 
Equations. Using the Pooled Cohort Equations to estimate the effect of initiating 
antihypertensive therapy with a reduction of SBP to 130 mm Hg on therapy, one would get a 
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counterintuitive and inappropriate result: the updated 10-year risk estimate of the patient 
would now be higher, at 19.5%. Although we know from clinical trial data that such 
antihypertensive therapy would in fact lower his risk for heart attack and stroke, the 
equations are not designed to reflect this change in an individual. Rather, the “updated” risk 
estimate reflects the natural history of a different individual who was treated for 
hypertension at some point before age 70 years and therefore is at higher risk because of 
longer burden and severity of elevated blood pressure. Thus, antihypertensive therapy use 
carries a positive coefficient in risk prediction models (indicating higher risk for those on 
therapy), because lowering blood pressure using medications does not reduce ASCVD risk 
to the same level as an individual who always had the lower blood pressure level in the 
absence of medications.47
Rationale for the Million Hearts Longitudinal ASCVD Risk Assessment Tool
In developing the Million Hearts Model to estimate the effect on change in ASCVD risk 
with evidence-based therapies, we judged that the optimal approach is to estimate the 10-
year predicted “natural history” risk of ASCVD, and then to simulate the expected average 
risk reduction associated with a given therapeutic intervention. In addition, we judged that it 
would be useful to assess the updated risk for ASCVD at a follow-up visit in a patient who 
has adopted a risk-reducing therapy (eg, blood pressure–lowering or statin medications) 
based on the actual observed change in the blood pressure or LDL-cholesterol, or the 
institution of aspirin or cessation of smoking. Our objective was to create an innovative tool 
that will assist policymakers, clinicians, and patients to estimate the expected effects of 
different preventive interventions, used singly and jointly, on ASCVD risk reduction in the 
Medicare population. The specific intent was to provide this tool as a basis for estimating 
projected/expected ASCVD risk reduction and actual/achieved risk reduction as a means for 
the CMMI to estimate physician performance in reducing ASCVD risk among high-risk 
Medicare beneficiaries.
A secondary goal was to create a tool applicable to a wider age range, including younger 
patients. Previous attempts have not been based on a systematic evidence review to 
determine the beneficial and harmful effects of the interventions, have not incorporated 
measures of variance in their estimates, and have not used the current US risk assessment 
paradigm based on the Pooled Cohort Equations.28 We therefore developed the novel 
Million Hearts Longitudinal ASCVD Risk Assessment Tool specifically for the CMMI 
Medicare program and describe its background and use in the text that follows. Use of the 
tool in other patient groups and clinical settings could be considered in the future if 
appropriate validation studies suggest its utility.
METHODS OF TOOL DEVELOPMENT
State of the Science and Gaps in Knowledge
The effects of some of the Million Hearts ABCS interventions on fatal and nonfatal ASCVD 
outcomes have been estimated previously through individual systematic reviews. However, 
to our knowledge, there are no reports that have summarized the effects of these 
interventions in primary prevention using a rigorous, transparent search, with comparison, 
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evaluation, and synthesis of systematic reviews through what is known as an overview of 
systematic reviews.
Furthermore, because some individuals with increased risk for ASCVD are eligible for 
multiple treatments, it was important to attempt to quantify the effects of concomitant 
preventive treatments. We may assume that the effects of multiple treatments are simply 
additive because most randomized controlled trials of aspirin, blood pressure–lowering 
therapies, and statins have included individuals who are on additional risk-reducing drug 
therapy. However, there exists the possibility of interaction effects that might be negative or 
positive. A positive interaction indicates effects of multiple preventive interventions that 
exceed the additive estimate (ie, the whole greater than the sum of the parts). Conversely, a 
negative interaction could occur if the effects of multiple interventions are less than expected 
from simple addition. A number of scenarios could lead to negative interactions, such as 
floor effects, in which there is a minimum event rate associated with risk factors below 
which interventions cannot further lower risk, or less-than-anticipated reductions in risk 
from aspirin in the setting of concomitant tobacco cessation or initiation of cholesterol-
lowering therapy. The potential for interactions requires a detailed evidence review to 
incorporate these effects into models that attempt to estimate the impact of risk modification 
from simultaneous interventions.
The website QIntervention 2014 (qintervention.org)48 aims to provide information to 
clinicians and patients on changes in ASCVD risk based on individual or concomitant 
interventions with blood pressure–lowering therapy, statin therapy, and tobacco cessation. 
However, the meta-analysis used to inform the effect estimate of statins has not been 
updated in >5 years, the website does not currently incorporate the effect of aspirin, and the 
effect of blood pressure–lowering treatment is erroneously47 estimated to be the same as the 
risk based on the same blood pressure levels without treatment. These features limit its 
usefulness.
Regarding the effects of combinations of interventions, some might argue that these were 
quantified in trials such as Steno-2.49,50 However, in addition to recommendations for more 
intensive drug therapy with aspirin, statin, and ACE-inhibitor use, Steno-2 included a 
behavioral component and more frequent office visits as components of a complex 
intervention.51 Combination drug therapy trials with either a factorial design (eg, the 
ASCOT-LLA [Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm])52 or 
fixed-dose combination therapy trials53 may be better suited to address this question of 
whether concomitant therapy with a combination of aspirin, blood pressure–lowering 
therapies, statins, or all of these leads to effects similar to those that would be predicted 
based on the individual drug effects. We also judged that there were undoubtedly other 
studies that inform the interaction of multiple interventions that could be identified with a 
systematic review approach.
To address these gaps in knowledge, we leveraged the infrastructure of the Cochrane Heart 
Group United States Satellite to derive the best available quantitative evidence on the 
expected effects of risk-reducing therapies (the ABCS) for ASCVD. We then combined 
these results with the predicted baseline risks for patients derived from the 2013 Pooled 
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Cohort Equations to estimate projected and achieved ASCVD risk reduction benefits over 
time.
Systematic Review of ABCS Therapies in ASCVD Risk Reduction
The detailed methods and results of the systematic review have been published.6 Briefly, we 
used standardized methods outlined in the Cochrane Handbook of Systematic Reviews54 
(www.handbook.cochrane.org) for the performance of an overview of systematic reviews for 
each of the following interventions for primary ASCVD prevention: aspirin, blood pressure–
lowering therapy, statins, and pharmacologic tobacco cessation strategies. Of note, we 
focused specifically on statins for cholesterol management because of the extensive evidence 
base and endorsement of statins by numerous guidelines as the primary means for 
management of LDL-cholesterol to reduce ASCVD risk.22,55
We created separate protocols and search strategies for each overview and published each 
protocol on PROSPERO (International Prospective Register of Systematic Reviews, http://
www.crd.york.ac.uk/PROSPERO/; Registration No. CRD42015023444). We selected 
systematic reviews of randomized clinical trials involving patients without prevalent 
ASCVD to derive treatment effect estimates that applied to a primary prevention population. 
We compared the effects of each intervention reported in the original systematic reviews, 
assessed the methodological quality of each systematic review using the AMSTAR tool 
(Assessment of Multiple SysTemAtic Reviews),56 and assessed the overall quality of 
evidence using the GRADE methodology (Grading of Recommendations Assessment, 
Development and Evaluation).57
As described below, all available data from clinical trials have reported only the intermediate 
end point of successful tobacco cessation/abstinence with no trials powered to detect 
differences in clinical outcomes. Although this is an important outcome, it did not address 
the needs of the tool. We therefore performed a separate literature search to estimate the 
ASCVD risk reduction achieved with tobacco cessation. By consensus, and in consultation 
with CMMI and CAMH, we selected 2 articles58,59 that used the most rigorous methodology 
to estimate longitudinal risk reduction for stroke and myocardial infarction associated with 
tobacco cessation. Notably, it was also not feasible to estimate the effects of lifestyle 
interventions on ASCVD event reduction in the near term. The widely differing approaches 
and scope of lifestyle interventions made them difficult to compare, or replicate, and data on 
hard outcomes for ASCVD events are sparse, as indicated in the AHA/ACC 2013 lifestyle 
management guidelines.60 Nonetheless, the importance of background and ongoing 
therapeutic lifestyle change is acknowledged, as all clinical trials of drug therapy for 
ASCVD risk reduction have been performed in the context of advice for lifestyle changes. 
Further, changes in risk factor levels ascribed to behavior changes will be captured through 
updated risk factor estimates in the risk assessment tool.
Systematic Review of Combination Preventive Therapies
To compare the effect of concomitant treatment against additive treatment, we performed a 
systematic review of randomized clinical trials including individuals who did not have 
ASCVD, with or without diabetes mellitus.6 We searched for trials that had assessed the 
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effects on ASCVD risk of concomitant drug treatment (compared with single component 
treatment alone) using any one of the following combinations: aspirin + blood pressure–
lowering therapy; aspirin + statin therapy; blood pressure–lowering + statin therapy; or 
aspirin + blood pressure–lowering therapy + statin therapy.
To compare the effects of concomitant treatment with the predicted, additive effects from 
individual treatments, we used data derived from both systematic reviews, including 
subgroup comparisons, where available. Based on our findings (detailed below), there were 
few trials that directly addressed this question, but we found no evidence for either a positive 
or negative interaction. Observational studies were not considered because of their inherent 
increased risks of bias, particularly when evaluating the effects of interventions. An 
alternative methodology to evaluate the potential effect modification of concomitant 
treatment would be to perform meta-regressions of systematic reviews on aspirin, blood 
pressure–lowering, and cholesterol–lowering therapy, where the presence or absence of 
concomitant therapy would serve as the explanatory variable. This approach was rejected 
because of the expected instability of such estimates.
Development of Million Hearts Longitudinal ASCVD Risk Assessment Tool
We created a spreadsheet-based tool (http://circ.ahajournals.org/lookup/suppl/doi:10.1161/
CIR.0000000000000467/-/DC2) that allows users to enter data on risk factor levels at a 
baseline visit, and that provides an age-, sex-, and race-specific 10-year ASCVD risk 
estimate for men and women based on the 2013 Pooled Cohort Equations.28 Using an 
iterative development process, and with frequent consultation with the CAMH and CMMI 
teams as well as other contractors, we developed the means for estimating the projected/
expected average risk reduction conferred by any of the 4 Million Hearts “ABCS” 
interventions. This prospective risk reduction (as determined by the systematic reviews 
described previously) was represented as an updated projected 10-year ASCVD risk after:
• Initiation or continuation of aspirin alone;
• Initiation or intensification of blood pressure–lowering therapy alone;
• Initiation of moderate-intensity statin, or intensification from moderate-intensity 
to high-intensity statin alone;
• Achievement of successful tobacco cessation alone; or
• All possible combinations of the above therapies (as relevant, see below).
We conducted extensive sensitivity analyses to include all possible therapy combinations and 
account for all plausible scenarios of risk factor changes. To avoid overestimation of the 
potential effects of therapies in combination, as described below, we included “floor” values 
of absolute risk, below which projected risks with interventions cannot go, which were 
calculated based on the predicted risk of individuals with untreated optimal levels of all risk 
factors at the same age, sex and race.
We also created an additional feature to allow for estimation of updated 10-year risk for 
ASCVD based on a given patient’s baseline risk and achieved change in risk factor levels at 
follow-up. The data from the systematic literature reviews were used to provide estimates of 
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ASCVD risk reduction associated with observed adherence to aspirin therapy, absolute 
change in SBP, absolute change in LDL-cholesterol, and successful tobacco cessation over 
different durations. Again, extensive iterative testing was performed to consider all possible 
scenarios and combinations of risk factor levels at follow-up (including both improvement 
and worsening of risk factor levels), with extensive input from the CMMI and CAMH teams 
as well as other contractors. We judged that both “floor” and “ceiling” values were needed to 
reflect plausible thresholds below (or above) which improvements (or worsening) in risk 
factors would not be associated with additional changes in ASCVD risk. Floor values were 
applied as described previously. Ceiling values were applied when, at a follow-up visit, a 
patient had a new risk factor (eg, had started smoking) or worsened levels of a risk factor 
(eg, higher level of SBP). In these cases, the updated risk value could not be higher than the 
ceiling of the risk of someone who had always been a smoker (or had that blood pressure 
value) at the same age and risk factor levels.
THE MILLION HEARTS LONGITUDINAL ASCVD RISK ASSESSMENT TOOL
Effects of Risk-Reducing Therapies
The results of the systematic reviews, which were performed to inform the tool, have been 
previously published.6 Briefly, from 1,967 identified reports, 35 systematic reviews of 
randomized clinical trials were identified, including 15 reviews of aspirin, 4 of blood 
pressure–lowering therapy, 12 of statins, and 4 of tobacco cessation drugs. Methodological 
quality varied, but 30 were judged to be of sufficient quality based on AMSTAR ratings. 
Using the highest quality evidence, the effects aspirin, blood pressure–lowering therapy, 
statins, and smoking cessation on ASCVD risk are summarized in Table 2.
High-quality evidence indicated that, compared with placebo, use of aspirin reduced the 
risks for ASCVD (relative risk [RR], 0.90; 95% confidence interval [CI], 0.85–0.96). Of 
note, risk reduction was similar for men and women, but effects were greater for CHD 
reduction in men and stroke reduction in women.6
Blood pressure–lowering therapy was associated with a 16% reduction in CHD events (RR, 
0.84; 95% CI, 0.79–0.90), and a 36% reduction in stroke (RR, 0.64; 95% CI, 0.56–0.73) 
with relatively modest decreases in blood pressure (6/3 mm Hg) associated with treatment.6 
These data were used to scale the achieved observed risk reductions for SBP level at the 
follow-up visit, with an expected RR of 0.73 for initiation of blood pressure–lowering 
therapy overall, and a RR of 0.65 per 10 mm Hg actual SBP lowering.
High-quality evidence for statins revealed a 25% reduction in major ASCVD events (RR, 
0.75; 95% CI, 0.70–0.81), and reductions in fatal and nonfatal CHD and stroke events. The 
mean difference in LDL-cholesterol associated with use of a statin was 1.00 mmol/L (95% 
CI, 0.85–1.16) or 38.7 mg/dL (95% CI, 32.9–44.9).6 Treatment effects standardized per 1 
mmol/L reduction in LDL-cholesterol were also reported by the Cholesterol Treatment 
Trialists for major vascular events (RR, 0.75; 95% CI, 0.70–0.80).17,18 Therefore, these 
values were used to scale the achieved observed risk reductions for LDL-cholesterol levels at 
the follow-up visit.
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Tobacco cessation drugs increased the odds of continued abstinence at 6 months (odds ratio 
range, 1.82 [95% CI, 1.60–2.06] to 2.88 [95% CI, 2.40–3.47]), but direct effects on ASCVD 
events were poorly reported.6 We therefore performed a separate literature review and, after 
consultation within the team and discussion with biostatistical and content experts, as well 
as with CAMH and CMMI, we elected to use the studies by Lee et al58,59 to estimate time-
dependent effects of successful smoking cessation on heart attack and stroke risk reduction 
up to 4 years after baseline. As a result, the combined estimates for risk reduction associated 
with smoking cessation are 15% at 1 year (>6–18 months’ follow-up), 27% at 2 years (>18–
30 months), 38% at 3 years (>30–42 months), and 47% at 4 years (>42 months). Because 
the risk reduction estimates for aspirin, blood pressure–lowering, and statins were based on 
trials with typical follow-up exceeding 2 years, we used the 2-year estimate for smoking 
cessation as the basis for prospective risk reduction estimation.
Aspirin increased the risk for major bleeding (RR, 1.54; 95% CI, 1.30–1.82), and statins did 
not increase overall risk for adverse effects (RR, 1.00; 95% CI, 0.97–1.03). Adverse effects 
of blood pressure–lowering therapy and tobacco cessation drugs were not possible to 
characterize systematically because they are inconsistently reported in the trials and poorly 
reported among systematic reviews including people without established vascular disease.6
In our systematic review evaluating potential interaction with combination therapy, we 
identified 4 factorial, randomized controlled clinical trials61–64 including 21,358 participants 
that evaluated these combinations:
• Blood pressure–lowering therapy + aspirin versus blood pressure–lowering 
therapy;
• Blood pressure–lowering therapy + statin versus blood pressure–lowering 
therapy;
• Blood pressure–lowering therapy + statin versus statin.
We found no evidence of an interaction among these combinations in terms of effects on 
ASCVD events, blood pressure, or lipid levels, but power to detect differences was limited 
because of small sample sizes or low event rates. Three of 4 studies had a high risk of bias 
across at least 1 domain. We also separately examined the ASCOT-LLA trial results,52 
which did not meet inclusion criteria for our systematic review (≥10% of participants in the 
trial had prevalent vascular disease), and found no evidence of treatment interaction. Overall, 
there does not appear to be evidence of any interaction effect of combination therapy for the 
primary prevention of ASCVD, but we rated the quality of evidence as low, downgrading 
because of study limitations and imprecision. Data published subsequent to our systematic 
review search from the HOPE-3 trial (Heart Outcomes Prevention Evaluation) appear 
consistent with simple additive effects and lack of interaction with combination blood 
pressure–lowering and statin therapy.15
Million Hearts Longitudinal ASCVD Risk Assessment Tool
The Million Hearts tool is intended to identify candidates for primary prevention therapies 
and assist in their management. Use of the tool occurs in 3 steps: (1) estimating the baseline 
10-year risk for ASCVD; (2) considering the potential benefits of risk-reducing therapies for 
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a given patient in the context of a patient-clinician discussion and shared decision-making; 
and (3) assessing the updated ASCVD risk based on the response to therapy. The User’s 
Guide (Appendix: http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.
0000000000000467/-/DC1) provides detailed instructions on use of the Million Hearts tool. 
An example of use of the tool for a patient is provided in Figure 1.
Step 1: Estimating the Baseline 10-Year Risk—On the first tab of the spreadsheet, 
the baseline 10-year ASCVD risk estimate is calculated using the ACC/AHA 2013 Pooled 
Cohort Equations,28 which provide sex- and race–specific 10-year estimates of ASCVD risk. 
The Pooled Cohort Equations were developed from samples of black and non-Hispanic 
white men and women who were 40 to 79 years of age, apparently healthy, and free of a 
previous history of nonfatal myocardial infarction (recognized or unrecognized), stroke, 
heart failure, percutaneous coronary intervention, coronary artery bypass surgery, or current 
atrial fibrillation. Patients with end-stage renal disease were not included in the derivation 
sample; such patients require individualized care with respect to use of aspirin and blood 
pressure–lowering therapies, and data on use of statin medications in patients with end-stage 
renal disease do not indicate overall benefit. For some patients with symptomatic or 
advanced heart failure, similar considerations and individualized decision-making may be 
necessary. However, recent data reinforce the importance of ASCVD risk-reducing therapies 
even among patients with heart failure of ischemic etiology.20 Therefore, the Million Hearts 
Longitudinal ASCVD Risk Assessment Tool is intended for use in a broad population aged 
40 to 79 years and eligible for primary prevention of ASCVD, with the exclusions noted 
previously. For older (and younger) individuals, guidelines recommend individualized care 
decisions. Patients with LDL-cholesterol of at least 190 mg/dL may have familial 
hypercholesterolemia and should be evaluated and considered for statin therapy regardless of 
age and estimated 10-year ASCVD risk.
The patient’s 10-year ASCVD risk is estimated by entering data in the red cells (Figure 2) 
on the patient’s sex, age, race/ethnicity, total and HDL-cholesterol levels, SBP, treatment for 
hypertension, history of diabetes mellitus (ever) and current smoking status (within the past 
year). Of note, additional data (LDL-cholesterol levels, statin treatment, aspirin therapy) are 
also collected during this phase to provide context for the projected risk reduction and to 
provide baseline values for updating ASCVD risk at follow-up visits.
After entering the baseline risk factor levels, the user is presented with the baseline 10-year 
ASCVD risk estimate (Figure 3). Of note, this is a sex- and race–specific estimate for a 
black or non-Hispanic white man or woman. For individuals of other race/ethnic groups, the 
relevant sex-specific equation for non-Hispanic whites is used, as recommended by the 
guidelines. These estimates may overestimate risk somewhat in Asian/Pacific Islander-East 
Asian Americans and Hispanic/Latino Americans, especially Mexican-Americans; they may 
underestimate risk somewhat in API-South Asian Americans, Asian/Pacific Islander-Other 
groups, Puerto-Ricans, and in American Indians/Alaska Natives. The calibration for 
individuals in “Other/Mixed Race” race/ethnic groups is uncertain. In the patient scenario in 
Figure 1, the 10-year risk estimate is 30.8% for a 70-year-old black man who is a current 
smoker with no history of diabetes mellitus, with an untreated total cholesterol of 240 mg/dL 
and HDL-cholesterol of 40 mg/dL, and an untreated SBP of 160 mm Hg. This should be 
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interpreted as follows: if we had 100 patients like this man, then we estimate that 31 of them 
will have or die from a heart attack or stroke in the next 10 years.
Step 2: Considering Potential Benefits of Therapies, Alone and in 
Combination—In addition to the baseline 10-year ASCVD risk estimate, on the first tab of 
the spreadsheet users will see the projected 10-year ASCVD risk that would be associated 
with institution of specific preventive therapies (Figures 1 and 3) as designated for each row. 
These estimates are a function of the baseline predicted 10-year risk from for the patient and 
the expected average relative risk reduction associated with a given therapy experienced by 
participants in randomized clinical trials, using the data described previously from the 
systematic reviews. Of note, the risk reduction estimates come from randomized controlled 
trials that have tended to last for 3 to 5 years, so it is assumed that patients who would start a 
medication would stay on it for at least that period of time, and adhere to the therapy 
similarly to participants in the trials. Logic models have been applied so that patients cannot 
receive an expected risk reduction for therapies that are not relevant. For example, if a 
patient is already a nonsmoker, users will see “NA” (not applicable) appear in rows where 
“stop smoking” would be a strategy. Similarly, for patients with estimated 10-year ASCVD 
risk below 5%, users will see “NA” appear in rows where statin use or intensification would 
be added, given that the guidelines do not recommend consideration of statin therapy for this 
group. Statin use at baseline does not affect the baseline 10-year risk estimate—the on-
treatment values of total cholesterol and HDL-cholesterol should be used for the risk 
estimate, and credit for further potential reduction in LDL-cholesterol is only given if the 
patient is on a moderate dose statin and could escalate to a high-intensity dose to further 
lower their LDL-cholesterol.
For patients already taking blood pressure–lowering drugs, one can estimate the expected 
effect of additional medication. However, if a patient has a baseline SBP <120 mm Hg, or 
<130 mm Hg with diabetes mellitus, no additional benefit of SBP lowering is assumed, and 
addition of blood pressure–lowering drugs results in a response of “NA.” For patients with 
estimated 10-year ASCVD risk below 10%, users will see “NA” appear in rows where 
aspirin would be started because guidelines do not typically recommend consideration of 
aspirin therapy for patients with 10-year risk <10%. If the patient is taking aspirin therapy at 
baseline, the expected risk reduction for continuing aspirin is assumed to be the same as 
starting aspirin de novo, because it is uncertain how to quantify any increase in risk 
associated with aspirin cessation.
Additive effects of medications in combination are assumed for these and all other 
calculations of expected or updated risk. Finally, the values of projected ASCVD risk in the 
setting of therapies are subject to a floor effect, meaning that expected ASCVD risks that are 
reported with initiation/addition of preventive therapy cannot be lower than the predicted 10-
year ASCVD risk for someone with the same age and race/ethnicity category who has an 
optimal risk factor profile (total cholesterol, 170 mg/dL; HDL-cholesterol, 60 mg/d; SBP, 
110 mm Hg; nonsmoker; non-diabetic; and no blood pressure–lowering drugs). Users are 
also provided with statements regarding possible adverse effects of medications.
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These data are intended for use to guide the patient-clinician discussion recommended in the 
2013 ACC/AHA cholesterol guidelines.22 This patient-clinician discussion was 
recommended because the guideline panel wished to avoid automatic assignment (or 
nonassignment) of a statin to a patient simply because of their 10-year risk estimate, without 
an important discussion to add clinician judgment and patient preferences to the final 
decision, especially in primary prevention. Using the Million Hearts tool, the patient and 
clinician can see the projected absolute risk reduction associated with initiation and 
continuation of each therapy, or combinations of therapies, and weigh this in the context of 
other considerations, including patient preferences for taking medications, potential adverse 
drug reactions or interactions, and where they see the most “bang for the buck.”
It may be difficult to assign priority to treatment strategies when considering multiple risk-
reducing therapies. Figure 4 provides a suggested algorithm that may be used by clinicians 
and patients in the CMMI program in addition to the Longitudinal ASCVD Risk Assessment 
Tool if there is uncertainty regarding which approach should be considered first. After 
assessment of 10-year risk for eligible patients, counseling and efforts aimed at smoking 
cessation should be considered for all current smokers. Next, clinicians may consider blood 
pressure level and focus particularly on controlling patients with significantly elevated SBP 
(≥160 mm Hg). When blood pressure levels are lower, the relative benefits of statins or 
antihypertensive therapy, or both, should be considered. Finally, clinicians and patients may 
wish to consider low-dose aspirin therapy. The suggested clinical algorithm in Figure 4 can 
be informed by the results of the Million Hearts tool with regard to expected risk reductions 
from the various therapies, but it should not replace clinical judgment.
Step 3: Assessing the Updated ASCVD Risk at a Follow-Up Visit Based on the 
Response to Therapy—On a second tab, the spreadsheet provides 10-year ASCVD risk 
information and the potential for ASCVD risk reduction with selected preventive therapies 
for a provider and patient at a “follow-up” visit (Figures 1 and 5). The values from the 
baseline visit are carried forward from the values entered on the first tab of the spreadsheet. 
At the follow-up visit, users enter values only in the red cells. Continuous variables may 
have increased or decreased in the interim, and some categorical values may have changed: 
smokers may have become nonsmokers; nonsmokers may have initiated/resumed smoking; 
non–aspirin users may have started aspirin; aspirin users may have stopped; patients without 
diabetes mellitus may have developed diabetes mellitus; and patients may have started 
antihypertensive therapy. As noted below, individuals with diabetes mellitus at baseline are 
treated as still having diabetes mellitus, and those who required antihypertensive therapy at 
baseline are assumed to still require it.
After entering all of these values, users are presented with 3 different 10-year ASCVD risk 
estimates (Figure 6). The first is the baseline 10-year ASCVD risk estimate, which is the 
same as that provided on the first tab of the spreadsheet, from the patient’s age and risk 
factor values at the baseline visit. An updated 10-year ASCVD risk estimate represents what 
would have happened if nothing had been done after the baseline visit, providing the risk at 
the follow-up age that would have been present using the baseline risk factor values, if no 
interventions had been performed. Similar caveats apply to this risk estimate for sex/race-
ethnic groups as noted previously. Finally, users will see the actual updated 10-year ASCVD 
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risk associated with this patient’s status at follow-up. This value is a function of the baseline 
risk, the follow-up age, and the interim change in therapies and risk factor levels, which are 
themselves a function of response to therapy and adherence. The duration of smoking 
cessation (if relevant) and the measured changes in the follow-up values of LDL-cholesterol 
and SBP determine the updated actual risk estimate. For example, the risk associated with a 
1 mmol/L (~38.7 mg/dL) change in the value of LDL-cholesterol was 0.75 from the 
systematic reviews cited previously. The tool uses the actual change in LDL-cholesterol 
relative to (scaled to) the reported risk reduction. Thus, if a patient achieved a 0.5 mmol/L 
reduction (~19 mg/dL) in LDL-cholesterol, the risk reduction would be (0.75)0.5, equal to 
0.87. If the patient achieved a 2 mmol/L reduction in LDL-cholesterol (~78 mmol/L), the 
risk reduction would be (0.75)2, equal to 0.56.
Follow-up aspirin use/nonuse also influences the updated risk estimate. Likewise, incident 
diabetes mellitus or resumption/initiation of smoking would adversely affect the follow-up 
risk estimate. The values for the actual updated 10-year ASCVD risk estimate have floor and 
ceiling values applied. The floor value is calculated as the predicted 10-year ASCVD risk for 
someone with optimal risk factor levels at the follow-up age. The ceiling value is the 
predicted 10-year ASCVD risk calculated from the actual updated risk factor profile, 
including use of medications. To estimate the potential risk reduction that can be obtained 
with additional interventions being considered during the follow-up visit, users can modify 
the values of risk factors and treatments in the red cells (Figures 7 and 8) to obtain new risk 
estimates representing responses to new future treatment scenarios.
RECOMMENDATIONS FOR USE IN CLINICAL PRACTICE
Appropriate therapeutic lifestyle changes are recommended for all individuals, regardless of 
ASCVD risk. For example, heart healthy eating patterns (eg, DASH and Mediterranean-style 
eating patterns) can further improve adverse risk factor levels and reduce cardiovascular 
events.60,65 Participation in recommended amounts of physical activity has numerous 
cardiovascular health benefits and is associated with reduced risk and improved health-
related outcomes.60,66 Maintenance of appropriate body mass index, and weight loss for 
those in whom it is indicated, can contribute significantly to ASCVD risk factor control as 
well.60,67 Tobacco cessation is urged for current tobacco users at all ages regardless of 
ASCVD risk, given the numerous adverse health consequences of smoking and strong 
relationship between tobacco use and ASCVD events.
In selected individuals at higher ASCVD risk, evidence-based approaches using medications 
including aspirin, blood pressure–lowering medications, cholesterol-lowering medications 
are appropriate in addition to tobacco cessation strategies among those who use tobacco. In 
general, the higher the absolute risk for ASCVD, the greater will be the absolute benefit 
from these medications, with a correspondingly greater net clinical benefit. Net clinical 
benefit can be defined as the potential for absolute risk reduction (events avoided) compared 
with the absolute potential for significant adverse events from taking a medication. It can be 
represented by a comparison of the number-needed-to-treat less the number-needed-to-harm 
for a given medication, which must be interpreted using absolute risks and expected risk 
reductions. The Million Hearts tool provides baseline assessments of 10-year ASCVD risk 
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and projected risk reductions from institution of evidence-based medications that can be 
used as part of the guideline-recommended, patient-clinician discussion of risks and benefits 
from therapy.22 The tool also provides updated estimates of ASCVD risk based on 
individual patient response to therapies at follow up. Figure 1 with the patient scenario 
provides an example of how the Million Hearts Longitudinal ASCVD Risk Assessment Tool 
may be used to facilitate risk reduction in the clinical setting. The spreadsheet version of the 
tool is the original format, but is not the final user interface. An online version of this tool 
that was developed specifically for CMS and participating medical practices will be assessed 
in high-risk primary prevention Medicare patients as part of the Million Hearts 
Cardiovascular Risk Reduction Model. In addition, the ACC plans development of an app 
for mobile devices and an interactive web-based tool. Future work should assess the tool in 
other patient groups and clinical settings prior to its widespread application.
POTENTIAL LIMITATIONS
There are a number of potential limitations to the approach used to develop this tool. First, 
although the Pooled Cohort Equations are well calibrated for the broad US Medicare 
population of blacks and non-Hispanic whites,38 data are limited on their performance in 
other racial/ethnic groups. The 2013 ACC/AHA risk assessment guideline made weaker 
recommendations for these other groups, indicating that use of the equations for whites of 
the same sex seemed more appropriate than use of the equations for blacks, but that the non-
Hispanic white equations would be expected to overestimate true risk in Hispanic-
Americans (other than Puerto Ricans) and East Asian-Americans, and would be likely 
underestimate risk in Puerto Ricans, Native American, and South Asian-American groups.
Age is the most important correlate of ASCVD events, thus age is a major driver of the 
Pooled Cohort Equations risk. Therefore, even individuals with optimal levels of risk factors 
may have elevated 10-year risk estimates simply on the basis of their age. Chronological age 
represents time of exposure to risk factors; older people with optimal levels of all risk factors 
may, in fact, not have as high of a 10-year risk as the equations would predict. After age 65 
years, the prevalence of all optimal risk factor levels, and 10-year risk estimates <5%, is low 
in the United States.28,45,68–70 This reality is unfortunate from a public health perspective, 
yet may reduce the effect of this potential limitation in our estimates. The significance of 
this concern is limited in the context of the proposed use of this tool for the Million Hearts 
Cardiovascular Risk Reduction Model, which will focus on very high-risk individuals (10-
year predicted ASCVD risk >30%). Age alone cannot produce such high-risk estimates 
without significant concomitant risk factor burden.
The Pooled Cohort Equations provide a probability of disease; they do not provide 
prognostic certainty. They should be interpreted by a clinician or patient as in the following 
example. For a patient with specified risk factor levels, assume that the 10-year risk estimate 
for ASCVD is 20%. The correct interpretation of this result is not that an individual is at 
20% risk, but rather that if there were 100 such individuals, by the end of 10 years, one 
would expect that 20 of them, or 1 in 5, would have a major coronary or stroke event. 
Whether the individual patient in question would be 1 of the 20 affected or 1 of the 80 
unaffected during that time cannot be discerned from the risk estimate. However, as 
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discussed in detail in the 2013 ACC/AHA cholesterol guidelines, there is evidence for net 
clinical benefit (ie, likelihood that more events will be prevented than adverse events caused) 
for statins down to as low as ~7.5% 10-year ASCVD risk for using high-intensity statins and 
even lower for using moderate-intensity statins. Cost-effectiveness data44 further support 
these treatment thresholds, which were based on event rates in the control groups of statin 
primary prevention trials.
The Million Hearts Tool provides an “updated” 10-year risk estimate that is based on both 
the baseline risk and the expected benefit from a preventive intervention (ie, aspirin, blood 
pressure–lowering therapy, statin, or tobacco cessation, or combinations thereof). We 
applied the best available evidence of effect size for each of the interventions from the 
medical literature. However, in doing so, we are applying a group mean effect of treatment 
to an individual patient scenario, with uncertainty in the revised estimate, because of, 
heterogeneity in response to treatment. We note that this issue is relevant to all evidence-
based interventions in clinical practice.71 We have improved the confidence of the updated 
on-treatment risk estimate by scaling the risk reduction to the amount of change in SBP or 
LDL-cholesterol or duration of smoking cessation. It is likely that the group-level, that is, 
practice-level, estimates of changes in risk will be more accurate and precise than 
individual-based estimates of changes in risk. It is also likely that the imprecision of the 
updated risk estimates has limited impact in individuals at very high predicted risk. As the 
baseline 10-year risk is lower and approaches values <10%, the imprecision may be more 
meaningful.
The Million Hearts Tool focuses on the quantitative changes in risk that may occur with 
institution of drug therapies. The evidence base for these data is the clinical trials in which 
background advice for therapeutic lifestyle change has also been provided to participants. 
Whereas lifestyle improvement is a critical feature of ASCVD prevention, the complex 
interventions on diet, physical activity, weight and other factors that have been studied to 
date are heterogeneous and quantification of those results is beyond the scope of current 
efforts. Nonetheless, adopting therapeutic lifestyle change is likely beneficial largely through 
its impact on risk factors such as lipids and blood pressure, which are represented in the 
updated risk estimates provided by the tool.
During iterative testing and evaluation by an external group, concerns were raised regarding 
the amount of risk reduction associated with lowering of SBP. In multiple sensitivity 
scenarios, patients who achieve large amounts of SBP reduction (especially if >20 mm Hg) 
have substantial reductions in risk and frequently reach the floor value given that there is an 
additional risk reduction of 35% for each 10 mm Hg lowering of SBP. Accordingly, we 
performed a further systematic review and reexamined relevant data72–77 and also examined 
recent evidence synthesis analyses in the context of the recent SPRINT (Systolic Blood 
Pressure Intervention Trial) and HOPE-3 trials.14,15 Discussion was also undertaken to 
understand the potential contribution of regression-dilution bias to large risk reductions. 
After deliberation, we continued the current framework, with floor values for the amount of 
absolute risk reduction, and no additional reduction for SBP lowering <130 mm Hg for those 
with diabetes mellitus or <120 mm Hg for those without diabetes mellitus.
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Finally, we have considered whether there are floor effects to preventive therapies and 
ceiling effects after adverse changes in risk factor levels. Extensive prior research has 
defined an optimal risk profile that is associated with extremely low lifetime risks for 
development of ASCVD in middle-aged and older individuals.68,78,79 During our testing of 
the tool, we have demonstrated that it is possible that individuals with elevated predicted 10-
year risks for whom we estimate updated predicted risks after institution of preventive 
therapy could have updated estimated risks that are lower than risk estimates for those with a 
truly optimal lifelong risk factor profile. This estimated outcome seems unlikely; published 
data from the National Heart, Lung, and Blood Institute–funded CARDIA and MESA 
(Multi-Ethnic Study of Atherosclerosis) cohorts demonstrate that treatment of elevated risk 
factor levels (eg, blood pressure) to optimal levels does not reduce risk to the same level as 
someone who always had optimal levels.47 Therefore, we have included floor effects for the 
projected or updated ASCVD risk estimates. Likewise, for instances in which patients return 
at a follow-up visit with elevations (rather than improvements) in SBP or LDL-cholesterol 
compared with their baseline values, or with incident diabetes mellitus or cigarette smoking 
in the interim, we included ceiling effects in the updated risk estimates to avoid 
overestimation of risk in these scenarios.
CONCLUSIONS AND IMPLICATIONS
The Million Hearts initiative is designed to reduce the burden of ASCVD in the United 
States and aims to prevent 1 million heart attacks and strokes by 2017. A key focus of this 
initiative is implementation of the ABCS in appropriate individuals at elevated risk. 
Substantial observational data support the current paradigm in primary prevention of 
ASCVD that the intensity of prevention efforts should match the absolute risk of the patient, 
with drug therapy reserved for those at higher predicted risk, in whom net clinical benefit 
will be greater.
In concert with Million Hearts, CMMI aims to assess whether incentivizing physicians to 
reduce ASCVD risk among Medicare beneficiaries at high predicted risk will result in lower 
rates of heart attacks and strokes. To support the proposed Million Hearts Cardiovascular 
Risk Reduction Model testing this hypothesis, we have developed the Longitudinal ASCVD 
Risk Assessment Tool. The tool provides a baseline 10-year ASCVD risk estimate for black 
and non-Hispanic white men and women. The tool also provides projected values of risk 
reduction that would be associated with institution of ABCS therapies alone or in 
combination; these estimates are based on the best available evidence from formal, high-
quality systematic reviews and meta-analyses. The projected risk reductions that are 
presented by the tool are based on average responses to the therapies, and are intended to 
guide decision-making around what preventive therapies to pursue (in the context of 
therapeutic lifestyle change) while considering net clinical benefit in the course of the 
guideline-recommended, patient-clinician discussion. Finally, the tool also provides updated 
10-year ASCVD risk estimates, to be calculated at a follow-up visit, which represents a 
more personalized updated risk estimate that reflects the actual response of a given patient, 
incorporating their individual changes in risk factor levels. This approach to personalized 
estimation of benefits from risk-reducing therapies may represent the next wave in clinical 
practice to help target therapies to those in whom they will provide the greatest benefit.
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The Million Hearts Tool has been developed to assist clinicians and patients to understand 
risk, to monitor patients’ risks over time, and to quantify potential benefits of preventive 
therapies based on high-quality evidence. It can also assist CMMI and clinical practices in 
monitoring risk in patient cohorts over time. Whereas it requires further assessment and 
validation in diverse clinical populations and scenarios, its implementation in the Million 
Hearts Cardiovascular Risk Reduction Model proposed by CMMI for high-risk Medicare 
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Figure 2. Data entry for estimation of 10-year risk for ASCVD at a baseline visit, for the example 
provided in the patient scenario (Figure 1)
AA indicates African American, or black; ASCVD, atherosclerotic cardiovascular disease; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; and WH, non-Hispanic white.
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Figure 3. Baseline 10-year ASCVD risk estimate for the patient scenario, and projected ASCVD 
risk if a given therapy or combination of therapies is used
ASCVD indicates atherosclerotic cardiovascular disease; and BP, blood pressure.
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Figure 4. Suggested clinical algorithm for prioritizing decisions regarding preventive therapies in 
the Million Hearts Cardiovascular Risk Reduction Model
*Patients with clinical atherosclerotic cardiovascular disease or LDL-C 190 mg/dL should be 
treated with high-intensity (or maximally tolerated) statin.
†Use USPSTF recommendations and consider the potential risk for major bleeding when 
considering use of aspirin. ACE-I indicates angiotensin-converting-enzyme inhibitor; ASA, 
aspirin; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; LDL-C, low-
density lipoprotein–cholesterol; MD, physician; and SBP, systolic blood pressure.
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Figure 5. Data entry for estimation of updated 10-year risk for ASCVD at a follow-up visit, for 
the example provided in the patient scenario (Figure 1)
AA indicates African American, or black; ASCVD, atherosclerotic cardiovascular disease; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; and WH, non-Hispanic white.
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Figure 6. Ten-year ASCVD risk values for use at a follow-up visit: 10-year ASCVD risk estimate 
at baseline visit for the patient scenario in Figure 1, 10-year ASCVD risk at follow-up if nothing 
had been done in the interim, and updated 10-year ASCVD risk based on patient’s current age, 
baseline risk, and achieved risk factor values at follow-up visit
ASCVD indicates atherosclerotic cardiovascular disease.
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Figure 7. Data entry for estimation of future 10-year risk for ASCVD after a follow-up visit if a 
statin was started, with reduction of LDL-cholesterol to 100 mg/dL, for the example provided in 
the patient scenario in Figure 1
AA indicates African American, or black; ASCVD, atherosclerotic cardiovascular disease; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; and WH, non-Hispanic white.
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Figure 8. Ten-year ASCVD risk values for use at a follow-up visit: 10-year ASCVD risk estimate 
at baseline visit for the patient scenario in Figure 1, 10-year ASCVD risk at follow-up if nothing 
had been done in the interim, and updated 10-year ASCVD risk based on patient’s current age, 
baseline risk, and future projected risk factor values after initiation of a statin and continuation 
of current therapies
ASCVD indicates atherosclerotic cardiovascular disease.
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Table 1
Strategies of the Million Hearts initiative to prevent 1 million heart attacks and strokes.4
• Improving access to effective care





• Focusing clinical attention on the prevention of heart attack and stroke
• Activating the public to lead a heart-healthy lifestyle
• Improving the prescription and adherence to appropriate medications for the ABCS
ABCS indicates aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation.
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Table 2
Results of systematic review with relative risk estimates for ASCVD risk reduction.6
Therapy Estimated RR for ASCVD Events (95% CI) Quality of Evidence* Comment
Aspirin 0.90 (0.85–0.96) High
Increased risk for major 
bleeding (RR, 1.54; 95% 
CI, 1.30–1.82)
Blood pressure– lowering†
CHD: 0.84 (0.79–0.90) overall; 0.79 (0.72–0.86) per 
10 mm Hg reduction in SBP High Adverse effects poorly 
reportedStroke: 0.64 (0.56–0.73) overall; 0.54 (0.45–0.65) per 
10 mm Hg reduction in SBP High
Cholesterol-lowering (statin) 0.75 (0.70–0.81) overall; 0.75 (0.70–0.80) per 1 mmol/L [38.7 mg/dL] reduction in LDL-cholesterol High
No increased risk for 
adverse effects overall 
(RR, 1.00; 95% CI, 0.97–
1.03)
Smoking cessation‡
0.73 overall; 0.85 at 1 y (>6–18 mo follow up); 0.73 at 
2 y (>18–30 mo); 0.62 at 3 y (>30–42 mo); 0.53 at 4 y 
(>42 mo)
Not graded Adverse effects poorly reported
*
High quality of evidence indicates that further research is unlikely to change our confidence in the estimate of effect.
†
Aggregate relative risks for all ASCVD (CHD plus stroke) with blood pressure–lowering are 0.73 overall and 0.65 per 10 mm Hg reduction in 
SBP.
‡
Effects on ASCVD events poorly reported. Therefore these effect estimates were derived from Lee et al.58,59 ASCVD indicates atherosclerotic 
cardiovascular disease; CI, confidence interval; CHD, coronary heart disease; RR, relative risk; and SBP, systolic blood pressure.
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